<DOC>
	<DOCNO>NCT00195312</DOCNO>
	<brief_summary>The main purpose study learn whether study vaccine adjuvant ( drug use help immune response ) acceptable safety profile treat individual HIV . A second purpose study understand immune system respond study vaccine adjuvant . Understanding difference could useful several way . First , might help identify people whose disease likely respond study vaccine study adjuvant . Second , information might useful develop treatment people whose disease respond study vaccine adjuvant .</brief_summary>
	<brief_title>Study Evaluating Vaccine Adults With HIV</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Must HIV positive . Receiving stable HAART minimum 6 consecutive month immediately screen . CD4 Tcell count great 350 mm cubed/mL time screen report CD4 Tcell count le 250 mm cubed/mL time screen . Other Inclusions Apply Any chronic symptomatic infection HIV . History diagnose autoimmune disease ( currently active control ) . Use prior HIV vaccine ( prophylactic and/or therapeutic ) within one year screening ( document , unblinded placebo recipient previous clinical trial may participate without time restriction ) . Other Exclusions Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>